Response to the correspondence referring to our article “Development of an MSI-positive colon tumor with aberrant DNA methylation in a PPAP patient” by Pilar Mur, Claire Palles, Ian Tomlinson, Laura Valle

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Easton DF, Lesueur F, Decker B, Michailidou K, Li J, Allen J, et al. No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. J Med Genet. 2016;53:298–309.

  2. 2.

    Weber-Lassalle N, Hauke J, Ramser J, Richters L, Groß E, Blümcke B, et al. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. Breast Cancer Res. 2018;20:7.

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Yoichi Furukawa.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yamaguchi, K., Furukawa, Y. Response to the correspondence referring to our article “Development of an MSI-positive colon tumor with aberrant DNA methylation in a PPAP patient” by Pilar Mur, Claire Palles, Ian Tomlinson, Laura Valle. J Hum Genet 65, 515–516 (2020). https://doi.org/10.1038/s10038-020-0752-8

Download citation